• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by BridgeBio Pharma Inc.

    8/11/25 4:17:47 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001192591
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    BRIDGEBIO PHARMA, INC.
    SEC File Number
    001-38959
    Address of Issuer
    3160 Porter Drive
    Suite 250
    Palo Alto
    CALIFORNIA
    94304
    Phone
    (650) 391-9740
    Name of Person for Whose Account the Securities are To Be Sold
    CHARLES J HOMCY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    500002400000.0019116850408/11/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common07/01/2019Founders SharesISSUERCheckbox not checked5000007/01/2019Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    CHARLES J HOMCY
    3160 Porter Drive
    Suite 250
    Palo Alto � CA � 94304
    Common08/08/20251500006907905.00
    CHARLES J HOMCY
    3160 Porter Drive
    Suite 250
    Palo Alto � CA � 94304
    Common08/08/2025500002302295.00
    CHARLES J HOMCY
    3160 Porter Drive
    Suite 250
    Palo Alto � CA � 94304
    Common08/08/2025500002302220.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/11/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/08/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Charles Jude Homcy

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $BBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    7/30/2025$56.00Outperform
    Raymond James
    7/21/2025$66.00Buy
    Truist
    7/14/2025$70.00Buy
    Jefferies
    7/9/2025$60.00Perform → Outperform
    Oppenheimer
    6/17/2025$49.00Outperform
    Wolfe Research
    3/31/2025$50.00Buy
    Redburn Atlantic
    10/16/2024Sector Outperform
    Scotiabank
    10/3/2024Perform
    Oppenheimer
    More analyst ratings

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:49:25 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:46:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/13/24 4:00:10 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the "committee") approved equity grants in the form of restricted stock units ("RSUs") to new employees under the Company's Amended and Restated 2019 Inducement Equity Plan (the "Plan"). The committee approved: (i) on September 5, 2025, RSU grants covering an aggregate of 33,684 shares of the Company's common stock to 13 new employees; (ii) on August 4, 2025, RSU grants covering an aggregate of 32,145 shares of the Company's co

    9/10/25 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

    - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline - Encaleret was well-tolerated with no serious adverse events reported over the study period - Based on these findings, BridgeBio intends to initiate a registrational clinical study of encaleret, an orally-administered investigational therapy, in chronic hypoparathyroidism in 2026 PALO ALTO, Calif., Sept. 06, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical compa

    9/6/25 2:30:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

    PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company's Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1). Dr. Gafni will provide an overview of ADH1, specifically focusing on pathoph

    9/3/25 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    SEC Filings

    View All

    SEC Form 144 filed by BridgeBio Pharma Inc.

    144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

    9/5/25 4:46:07 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BridgeBio Pharma Inc.

    144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

    8/20/25 4:23:45 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

    SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    8/14/25 8:32:31 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccormick Frank sold $3,933,544 worth of shares (74,000 units at $53.16) and exercised 74,000 shares at a strike of $11.92 (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    9/8/25 6:06:31 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Neil sold $4,175,835 worth of shares (80,000 units at $52.20) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    9/8/25 6:05:34 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Trimarchi Thomas sold $2,090,081 worth of shares (42,237 units at $49.48), decreasing direct ownership by 9% to 421,081 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    8/22/25 4:58:52 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on BridgeBio Pharma with a new price target

    Raymond James resumed coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $56.00

    7/30/25 7:32:47 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on BridgeBio Pharma with a new price target

    Truist initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $66.00

    7/21/25 8:31:03 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on BridgeBio Pharma with a new price target

    Jefferies initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $70.00

    7/14/25 8:47:47 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Leadership Updates

    Live Leadership Updates

    View All

    BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope

    7/23/24 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

    The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci

    5/2/24 7:00:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

    PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation

    10/25/21 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Financials

    Live finance-specific insights

    View All

    BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

    PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will b

    7/22/25 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

    PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be a

    4/22/25 7:30:37 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

    - As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first

    2/20/25 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    11/6/24 5:04:05 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    9/17/24 6:41:54 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    8/20/24 8:42:04 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care